Regulatory lapses have been hurting the industry since long. In several instances earlier, such issues had eroded the financials of top-tier companies. Of late, many companies have again come under the USFDA’s lens. Why has one of the world’s leading suppliers of medicines not learnt from its past, and how can it get its act together?
Data-integrity woes have come back to haunt Indian pharma. How can it deal with the USFDA’s glare?
